Copyright © by The Journal of Bone and Joint Surgery, Incorporated Morimoto et al.

 $Effect of Intermittent Administration of Teriparatide (Parathyroid Hormone 1-34) on Bone Morphogenetic Protein-Induced Bone \dots http://dx.doi.org/10.2106/JBJS.M.01097$

Page 1 of 1




Fig. E-1 Regions of interest for the evaluation of the newly formed bone are shown. In a spine that has not been operated on, the region contains almost no bone mass except a small tip of the transverse process and a part of the facet joint (left). In the fused spine, the same region contains the newly formed bone, where originally no bone existed (right). 3D = three-dimensional.

TABLE E-I Treatment Groups*		
Group	Implanted Material	Injected Material
А	Collagen carrier only	Saline solution
В		PTH 1-34
С	Collagen carrier with 2 µg of rhBMP-2	Saline solution
D		PTH 1-34
E	Collagen carrier with 50 µg of rhBMP-2	Saline solution
F		PTH 1-34
*Each treatment group had eight spines. rhBMP-2 = recombinant human bone morphogenetic protein-2, and PTH 1-34 = parathyroid hormone 1-34 (teriparatide).		